Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02156336 · ClinicalTrials.gov registry record · Phase 4
Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
A Phase 4 study, sponsored by Horizons International Peripheral Group.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02156336 is a Phase 4 study that was terminated before completion, run by Horizons International Peripheral Group. The registered enrollment target is 4 participants.
The verdict
NCT02156336, a Phase 4 study, was terminated before completion, sponsored by Horizons International Peripheral Group.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if patients suffering from diabetic peripheral neuropathic pain treated with ranolazine will have a greater reduction in pain compared to placebo. Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical animal model of neuropathic pain, the investigators hypothesize that subjects randomized to ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-02-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02156336
The ClinicalTrials.gov registry entry for NCT02156336 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Horizons International Peripheral Group, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02156336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02156336 about?
NCT02156336 is a clinical study titled "Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)". The purpose of this trial is to determine if patients suffering from diabetic peripheral neuropathic pain treated with ranolazine will have a greater reduction in pain compared to placebo. Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical animal model of ne...
What is the current status of trial NCT02156336?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2014-05. Estimated completion is 2017-02-08.
What interventions are being tested in trial NCT02156336?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02156336?
This trial is sponsored by Horizons International Peripheral Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.